Details for New Drug Application (NDA): 022291

✉ Email this page to a colleague

NDA 022291 describes PROMACTA, which is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the PROMACTA profile page.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.

Summary for 022291

Tradename:	PROMACTA
Applicant:	Novartis
Ingredient:	eltrombopag olamine
Patents:	6

Pharmacology for NDA: 022291

Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Thrombopoietin Receptor Agonists UGT1A1 Inhibitors UGT1A3 Inhibitors UGT1A4 Inhibitors UGT1A6 Inhibitors UGT1A9 Inhibitors UGT2B15 Inhibitors UGT2B7 Inhibitors
Physiological Effect	Increased Megakaryocyte Maturation Increased Platelet Production

Suppliers and Packaging for NDA: 022291

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PROMACTA	eltrombopag olamine	TABLET;ORAL	022291	NDA	Novartis Pharmaceuticals Corporation	0078-0684	0078-0684-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0684-15)
PROMACTA	eltrombopag olamine	TABLET;ORAL	022291	NDA	Novartis Pharmaceuticals Corporation	0078-0685	0078-0685-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0685-15)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 25MG ACID
Approval Date:	Nov 20, 2008	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Nov 16, 2025
Regulatory Exclusivity Use:	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
Patent:	⤷ Subscribe	Patent Expiration:	Jan 13, 2026	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	⤷ Subscribe	Patent Expiration:	Feb 1, 2028	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 022291

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-002	Nov 20, 2008	⤷ Subscribe	⤷ Subscribe
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-001	Nov 20, 2008	⤷ Subscribe	⤷ Subscribe
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-003	Sep 8, 2009	⤷ Subscribe	⤷ Subscribe
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-002	Nov 20, 2008	⤷ Subscribe	⤷ Subscribe
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-004	Oct 20, 2011	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.